Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Omarigliptin). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Omaglip 25 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Route of administration: Omarigliptin tablets should be taken in oral route.Recommended dosage: The recommended dose of Omarigliptin is 25 mg once weekly as monotherapy or as add-on therapy for optimisation of glycemic control. If patient misses a dose, advice to take the missed dose as soon as possible and then follow the regular weekly dosing schedule. Never take two doses at one time. Renal impairment: The dosage in patients with severe renal dysfunction or with end-stage renal failure or in those requiring hemodialysis or peritoneal dialysis should be according to the following: Severe end-stage kidney failur- Men: CrCl>1.9: 12.5 mg once a week Women: CrCl >1.4: 12.5 mg once a week. Use in children and adolescents: Safety and efficacy of omarigliptin in children and adolescents have not been established.
Side Effects
The adverse effects of Omaglo are generally well tolerated. The most common side effects are nasopharyngitis, hypoglycemia, constipation, diarrhea, gastrointestinal problem, skin and subcutaneous tissue disorders.
Cautions & Contraindications
Warnings & Precautions
Omaglo should be administered with caution in following patients or conditions which might cause low blood sugar such as pituitary dysfunction or adrenal insufficiency; malnutrition, starvation, irregular dietary intake, lack of dietary intake or debilitated state; intense muscle movement; excessive alcohol intake and elder person. Caution should be taken in patients engaged in aerial work or operation of an automobile.
Contraindications
Omarigliptin is contraindicated in patients with hypersensitivity to omarigliptin or any other component of this product. It is also contraindicated in severe ketosis, diabetic coma or precoma in type 1 diabetes patients. Omarigliptin is contraindicated in severe infection in which glycemic control is desired by insulin injection, before and after surgery and in patients with severe trauma.